May 22, 2024

Stemline Therapeutics

Zug

OTHER

Therapeutic Area Manager Oncology, Switzerland - Deutschschweiz

Overview:

Therapeutic Area Manager Oncology, Switzerland - Deutschschweiz

Reports to Country Manager Austria & Switzerland

The Opportunity

The TAM is responsible for the sale and support of Stemline products to both existing and potential customers. The goals of this position are to acquire new customer business, increase market share through acquiring new accounts or expanding business in current customers, develop and encourage strong customer relationships, build brand loyalty, and to provide customer satisfaction.

It is a role with an extremely high level of autonomy, visibility, and the unique chance to influence how Stemline is positioned in Switzerland.

Responsibilities:

Identification of key local medical professionals in relevant disease areas for Stemline and establish and maintain professional relationships with these stakeholders.
Assessment of patient journeys, discovering gaps and setting up plans in collaboration with the cross-functional team to ensure that Stemlines’s medicines will effectively and safely reach the patients who need them.
Taking initiative and working hand in hand with Medical Affairs and Market Access in implementing disease awareness campaigns, and interdisciplinary professional projects in Switzerland in accordance with the respective strategic plans.
Provision of all relevant information related to approved Stemline products necessary to ensure their most effective and safe usage in the right patients according to clinical data, label and prescribing information.
Interaction with local Medical Affairs to implement the most effective product support measures ensuring correct product handling and application by the prescribing sites.
Development and implementation of appropriate measures within the agreed strategic objectives to drive in-label usage of Stemline's approved products within the right patient group as per respective label and prescribing information.
Providing support to medical professionals and treatment centres on any ordering and reimbursement aspects related to Stemline products.
Operational and strategic contribution to market development project plans in close collaboration with the local cross-functional team.
General support of various field market access activities in close collaboration and under the guidance of Market Access.
Ensuring full compliance in all customer engagement efforts according to Stemline's SOPs as well as local laws and regulations.

Qualifications:

Experienced KAM, at least 5 years of field experience in the pharmaceutical industry in Switzerland
Previous experience working in the area of Hematology/Oncology and preferred is experience in breast cancer
Proven interest/expertise in scientific and clinical aspects paired with an entrepreneurial attitude and a tenacious ambition for commercial success
Outspoken and positive attitude in benefit/price aspects of innovative pharmaceutical products
Robust understanding of local reimbursement mechanisms, willing to engage with and support centres in reimbursement aspects
Strong intellectual and communication skills
Highly self-motivated, hands-on and acting independently
The role will be 100% field-based covering the assigned territory, requiring a high level of travel and mobility
German (business fluent), English (good level)

Menarini Stemline is an equal-opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees

The Company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.

Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.

In 2022, the company launched the CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.

Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.